PMN (ProMIS Neurosciences) Inventory-to-Revenue : 0.00 (As of Dec. 2024)

View and export this data going back to 2005. Start your Free Trial

What is ProMIS Neurosciences Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. ProMIS Neurosciences's Average Total Inventories for the quarter that ended in Dec. 2024 was $0.00 Mil. ProMIS Neurosciences's Revenue for the three months ended in Dec. 2024 was $0.00 Mil.

ProMIS Neurosciences's Inventory-to-Revenue for the quarter that ended in Dec. 2024 stayed the same from Sep. 2024 (0.00) to Sep. 2024 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

ProMIS Neurosciences Inventory-to-Revenue Historical Data

The historical data trend for ProMIS Neurosciences's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProMIS Neurosciences Inventory-to-Revenue Chart

ProMIS Neurosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Inventory-to-Revenue

Get a 7-Day Free Trial

ProMIS Neurosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Inventory-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of ProMIS Neurosciences's Inventory-to-Revenue

For the Biotechnology subindustry, ProMIS Neurosciences's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProMIS Neurosciences's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where ProMIS Neurosciences's Inventory-to-Revenue falls into.

Save Embed

;

Save Embed

;

ProMIS Neurosciences Inventory-to-Revenue Calculation

ProMIS Neurosciences's Inventory-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

	Inventory-to-Revenue (A: Dec. 2024 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2023 )	+	Total Inventories (A: Dec. 2024 ))	/	count )	/	Revenue (A: Dec. 2024 )
=	( (0	+	0)	/	1 )	/	0
=	0					/	0
=	N/A

ProMIS Neurosciences's Inventory-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

	Inventory-to-Revenue (Q: Dec. 2024 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Sep. 2024 )	+	Total Inventories (Q: Dec. 2024 ))	/	count )	/	Revenue (Q: Dec. 2024 )
=	( (0	+	0)	/	1 )	/	0
=	0					/	0
=

ProMIS Neurosciences (NAS:PMN) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

ProMIS Neurosciences's Days Inventory for the three months ended in Dec. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2024 )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

ProMIS Neurosciences's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2024 )	/	Average Total Inventories (Q: Dec. 2024 )
	=	0	/	0
	=

ProMIS Neurosciences Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of ProMIS Neurosciences's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

ProMIS Neurosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProMIS Neurosciences Inc (NAS:PMN) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

23J0:Germany 23J0:Germany

Address

1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2

Website

https://www.promisneurosciences.com

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Executives

Neil Cashman	director, officer: Chief Scientific Officer	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Madge K. Shafmaster	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Patrick D. Kirwin	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Larry Douglas Altstiel	officer: Chief Medical Officer	C/O NEUROTROPE, INC., 50 PARK PLACE, SUITE 1401, NEWARK NJ 07102
Daniel E. Geffken	officer: Chief Financial Officer	DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Jeremy M. Sclar	10 percent owner	33 BOYLSTON STREET, SUITE 3000, CHESTNUT HILL MA 02467
Gail M Farfel	director, officer: Chief Executive Officer	142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Max A. Milbury	officer: Principal Accounting Officer	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Gavin T. Malenfant	officer: Chief Operating Officer	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Johanne Kaplan	officer: Chief Development Officer	PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Eugene Williams	director, officer: Chairman and CEO	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Richard J. Gregory	director	830 WINTER STREET, WALTHAM MA 02451
Neil K Warma	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
William W Wyman	director	4 N. BALCH STREET, HANOVER NH 03755
Josh Mandel-brehm	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2